In recent years, the spectrum of clinical preventive risk management for carriers with GPVs of PALB2 has been extended to epithelial ovarian cancer and pancreatic cancer, with absolute risks at 3–5% and 5–10%, respectively, according to NCCN Guidelines® Version1.2022 (www.nccn.org, accessed on 19 November 2021). Here, PALB2 is linked to pancreatic neoplasm.